K. Buser

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Elizabeth A. Eisenhauer, W.W. ten Bokkel Huinink, Kenneth D. Swenerton et al. · Journal of Clinical Oncology · 1994 · 641 citations

Medicine, Oncology, Pharmacology +16

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study

C. Seynaeve, Jan C. Schuller, K. Buser et al. · British Journal of Cancer · 1992 · 102 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy

Aron Goldhirsch, Richard Greiner, E. Dreher et al. · Cancer · 1988 · 51 citations

Medicine, Oncology, Surgery +17

Breast cancer: Pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics

K. Buser, Franziska Joncourt, H. J. Altermatt et al. · Annals of Oncology · 1997 · 47 citations · Full text

Medicine, Oncology, Pharmacology +14

Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients

R Joss, M. Bacchi, K. Buser et al. · Annals of Oncology · 1994 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +7